2Morrow is a leader in digital behavioral health, providing evidence-based health and wellness programs to some of the nation's largest employers, states, and health plans. Founded in 2011, 2Morrow combines behavioral science and smartphone technology to increase access to care. The company has helped over half a million people improve their lives through its digital health programs, which include unique bundles for behavioral health, tobacco cessation, and wellness strategies. With a focus on personal values and motivation, 2Morrow's programs are designed to drive meaningful change and are supported by extensive research, including over 20 studies and clinical trials.

4base Care is a leading precision oncology company focused on transforming cancer treatment in Asia and the Middle East through advanced genomic and digital technologies. They offer a range of products including somatic panels, hereditary cancer gene panels, and liquid biopsy cancer gene panels, which are designed to personalize cancer treatment based on genetic profiles. Their differentiation lies in their comprehensive approach that combines genomic testing with patient support services, ensuring a holistic care experience. With a strong emphasis on research and collaboration with healthcare providers, 4base Care is positioned to make significant impacts in the oncology market, enhancing patient outcomes and advancing precision medicine.

Access Vascular is a rapidly growing company that offers a suite of vascular access devices utilizing a novel, patented biomaterial featuring MIMIX® technology. This technology is designed to prevent common complications in vascular access, such as occlusions and replacements, leading to a better patient experience and potential savings of up to $1.8 million for large acute care hospitals. Their flagship products, Hydro PICC and Hydro MID, have demonstrated statistically significant reductions in complications compared to standard polyurethane catheters, positioning Access Vascular as a leader in innovative vascular access solutions.

Aevice Health is a pioneering company focused on transforming the management of chronic respiratory diseases through its innovative product, the Aevice MD, a non-invasive wearable stethoscope. This device allows for continuous monitoring of lung sounds and vital signs, enabling healthcare professionals to track patient responses to treatment plans effectively. By providing hospital-quality insights directly from home, Aevice Health enhances accessibility to respiratory care, reduces the risk of adverse events, and drives patient engagement. The company has received multiple awards for its innovation in digital health, positioning it as a leader in the respiratory care market.

Potable rapid infection detection system

Alva Health is a Yale University technology spinout focused on revolutionizing stroke care through patented wearable devices that monitor for early signs of stroke. Their innovative technology aims to address the critical issue of timely medical intervention, as 90% of stroke victims do not receive care promptly. The company is positioned to significantly reduce avoidable healthcare spending associated with long hospital stays and rehabilitation, while improving patient outcomes through immediate connection to emergency responders. With a strong founding team of stroke experts and scientists, Alva Health is poised to lead in the neurotechnology market.

Ankr Health is a patient navigation and triage platform that leverages AI to empower cancer patients and caregivers by providing timely, accurate information and support. The platform offers features such as treatment navigation, side effect management, and personalized content tailored to individual needs, all designed by leading oncologists and surgeons. Ankr aims to improve patient outcomes and reduce healthcare costs by enhancing communication between patients and their healthcare teams. With a mission to simplify the cancer care journey, Ankr is positioned as a trusted resource for patients navigating complex treatment options.

Anumana is an AI-driven health technology company from nference, focused on building and commercializing AI solutions to enhance patient care in cardiology. The company leverages a vast dataset of electrophysiological data and patient history to develop investigational medical devices aimed at early diagnosis and intervention in cardiovascular diseases. Anumana's innovative algorithms, including ECG-AI and EGM-AI, are designed to improve clinical decision-making, enhance procedure accuracy, and integrate seamlessly into existing healthcare workflows. With a robust pipeline of FDA-ready algorithms and numerous peer-reviewed publications, Anumana is positioned to transform cardiac care and address significant healthcare burdens associated with undiagnosed cardiovascular conditions.

Aopia Biosciences, Inc. is a biotechnology company dedicated to providing revolutionary bioengineering solutions and tools for biomedical research, diagnostics, and therapeutic applications. Their flagship product, Nano EX™, is a next-generation EV isolation platform that offers unparalleled recovery and purity, making it a superior choice for researchers and clinicians. The company differentiates itself through fully automated processing, high scalability, and a commitment to advancing EV-based research and diagnostics. With a strong focus on innovation, Aopia is positioned to lead in the rapidly evolving biotechnology market, particularly in the areas of early disease diagnosis and treatment monitoring.

Astek Diagnostics is a medical device company developing the JIDDU system, an innovative clinical diagnostics platform that provides rapid infection confirmation for urinary tract infections (UTIs) and antibiotic sensitivity indication within one hour. This platform significantly enhances diagnostic speed and accuracy, reducing patient complications and healthcare costs. With a focus on addressing the growing issue of antibiotic-resistant UTIs, Astek aims to transform the standard of care, particularly benefiting women who are more prone to UTIs. The company is currently in partnership with key healthcare institutions and is on track for market entry in 2025, showcasing strong initial results and a commitment to improving patient care.

Atom Bioworks is a DNA-based nanomaterial company that specializes in developing innovative solutions for targeted drug delivery and rapid diagnostics. Their flagship products include the Apt LNP drug delivery system and the DNA Net disease detection platform, which leverage advanced DNA design and pattern recognition technologies. With a strong focus on healthcare applications, particularly in immunotherapies and diagnostics for infectious diseases and cancer, Atom Bioworks differentiates itself through its AI-enabled design software and high-affinity binding materials. The company is based in the biotech hub of Research Triangle Park, North Carolina, and has gained recognition for its potential impact in the life sciences sector.